Avid Bioservices Inc (CDMO)

[biopharm]

I do note that the critics are responsible for not one drug succeeding at the FDA nor for one dollar of biotech revenue. Dr Garnick is responsible for many tens of billions of dollars of biotech revenue.

The weight of the argument is now so heavily in favor of PPHM that the whole subject becomes tedious. There is not much more value in addressing this particular question.

When I play poker, I try to get my money in with favorable odds.
If I am lucky, I might find situations where the odds are 1.5-1 or 2-1 or 4-1 or at best 10-1. At the current P value the odds of this Phase II study being duplicated favorably in a larger Phase III study of similar design are 98%. I want to get my money in.

Garnick, realizing the odds, wants the study to be almost exactly the same except for the increase in "N". Why wouldn't he?? He uses the key code words "straightforward" and "derisk". Faced with these overwhelmingly favorable odds and the size of the NSCLC market as well as the larger overall potential of bavi ,---"If you were a BP, what would you do Madam????"

IMHO, stay cool, use weakness to further accumulate if you are able, and anticipate further major bullish news.

a good post by RRdog and combine all that with the knowledge that the Phase IIb trial results were "MUCH BETTER" than previously thought and we have one hell of a run coming up. Peregrine was sabotaged, the 3mg Bavi arm would have been 133% +++ better than previously reported and who knows, 150% or 300% or more? All I do know is even Brekken likes what he is seeing, and he is seeing 200-300% better results for overall response rates when some downstream drugs are combined with Bavituximab.

That just may make all downstream SOC, a much better SOC and a renewed patent life begins again.... or if required to do so, generics would work just as well I would think, and may not even need to deal with many BP's, if at all.